Biopharma and med-tech company deals and M&As: Abbott, Alvotech, Ambros, Amplitude, Avricore, Beyond Air, Bioarctic, BMS, Chai Discovery, Chong Kun Dang, Darmiyan ...

Despite Vertex Pharmaceuticals Inc.’s mostly positive phase III study results of a non-opioid for treating moderate to severe acute pain, the data for a key secondary endpoint show VX-548 is not as ...

In a deal worth $1.32 billion, Jazz Pharmaceuticals plc made plans to acquire Actio Biosciences Inc. and its lead epilepsy drug ABS-1230 earlier this month, ...

A compound targeting serotonin receptor 5-HT2A (5-HT2AR) signaling in the gut could activate antitumor immunity in colorectal cancer (CRC) and improve responses to immunotherapy without causing ...

Infinimmune Inc. raised $75 million in a series A round, co-led by Regeneron Ventures and Playground Global, to advance its IL-22-targeted IFX-101 and IL-13-targeted IFX-201 into the clinic in 2027 ...

Astronautx Ltd. has exercised an option under its neurology collaboration with Saniona AB granting the company exclusive worldwide rights to research, develop, manufacture and commercialize resulting ...

Remedium Bio Inc. has announced the initial closing of its planned $10 million series A financing as it advances its durable protein therapeutics platform toward first-in-human development.

The emerging field of cancer neuroscience is plotting out the ways in which the nervous system and tumors communicate and pointing to potential drug targets that could modulate the neuro-cancer ...

CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has patented compounds reported to be useful for the treatment of respiratory syncytial virus (RSV) infection.

The scientific community continues to make progress at uncovering the elements that could lead to a cure for HIV. The virus remains latent in reservoirs that are difficult to eliminate, so researchers ...

Frontier research uniting cancer biology and neuroscience is leading to new understanding of how tumors interact with the peripheral and central nervous systems to fuel their growth. Neural inputs ...

Shy Therapeutics LLC has developed and presented data for SHY-ONC6, a novel inhibitor of the proteasome 19S regulator particle (RP) ATPases for the potential treatment of hematological malignancies ...